What happens when Wegovy stops working — and what to do next

Why does weight loss stall on Wegovy when it was working before?

The short answer is that your body is doing exactly what bodies do. Semaglutide works by activating GLP-1 receptors that regulate appetite and slow gastric emptying, which reduces calorie intake. Early in treatment, that suppression of appetite is powerful and the deficit is large. As your body reaches a lower weight, your basal metabolic rate falls too (you simply need fewer calories to maintain the new weight) so the same dose produces a smaller ongoing deficit. This is adaptive thermogenesis, and it applies to every form of weight reduction, not just GLP-1 medicines.

There is also evidence from the STEP 1 trial, published in the New England Journal of Medicine, that average weight loss with 2.4 mg semaglutide peaks around weeks 60–68, with most of the effect established by six months. Slower progress after that point is within the expected range, not a signal that treatment has stopped working entirely. A quick check worth doing: look at your weight entries over the past four weeks rather than comparing last week to the week before. Short-term fluctuations driven by fluid, cycle phase or a heavier-salt weekend can look like a plateau when the four-week trend still shows gradual movement.

Separately, lifestyle factors that drift over time (portions creeping back up, less deliberate activity) can blunt semaglutide's effect without any change in the medicine itself. Protein intake and strength-based activity are particularly relevant; a prescriber or dietitian can help identify whether a lifestyle review would move things forward.

Is there a point at which the clinical guidance says Wegovy genuinely isn't working?

Yes, and it is defined. NICE's appraisal of semaglutide (TA875) states that if a person has lost less than 5% of their body weight after six months at the maintenance dose, the prescriber should consider whether continuing is appropriate. That threshold is there because semaglutide clearly works well for most people who reach a meaningful maintenance dose, but not for everyone. If you're approaching or past that six-month mark without meaningful progress, that conversation with your prescriber is exactly the right one to have.

It is worth distinguishing between two different situations. The first is someone who has lost weight steadily, reached a plateau, and is frustrated that the pace has stopped. The second is someone who has barely lost anything despite weeks on the maintenance dose. The clinical response to each is quite different. In the first case, the medicine is doing its job and the plateau may be managed. In the second, the prescriber may look at whether a different treatment (such as other licensed options available in the UK) might be a better fit.

What are the actual options if Wegovy has stopped working for you?

There is no single answer, and a prescriber has to lead this conversation. That said, the realistic routes include the following.

First, a clinical review of dose. The MHRA approved a 7.2 mg dose of Wegovy in January 2026, and a dedicated single-dose 7.2 mg pen followed in April 2026, for adults with a BMI of 30 or above. Some people who plateau on 2.4 mg may respond to the higher dose, though the decision sits with a prescriber and depends on tolerability. You can read more about how Wegovy works and its licensed doses on our treatment page.

Second, switching to a different licensed treatment. Tirzepatide (Mounjaro) is the only dual GIP and GLP-1 receptor agonist licensed for weight management in the UK. Because it activates two pathways rather than one, some people who plateau on semaglutide respond differently to tirzepatide. The SURMOUNT-5 head-to-head trial reported greater average weight loss with tirzepatide versus semaglutide 2.4 mg over 72 weeks in adults with obesity. Whether switching is appropriate is a clinical decision that depends on your health history, current response and tolerance.

Third, a thorough lifestyle review. This is not a consolation prize. Dietary protein, resistance exercise and sleep quality all affect how much weight someone loses on a GLP-1 medicine. Our prescribers address this as part of clinical review, not as an afterthought. You can also explore common questions about treatment on our FAQs page.

If you are weighing up the cost of continuing or switching, our Wegovy pricing page explains what a legitimate private prescription includes and how pricing is structured. One transparent price, no subscription.

Should you stop Wegovy entirely if it has plateaued?

Stopping is a significant decision, and not just because of cost. The evidence on what happens after stopping semaglutide is consistent: without continued treatment or very strong lifestyle support, most people regain a substantial proportion of the weight lost. If you want to understand the physiology in detail, our guide to what happens when you stop taking Wegovy covers why the appetite-suppressing effect reverses when the medicine clears and the biological drivers of weight regain return. You may also find it helpful to read about what happens when you stop using Wegovy, which looks at the same process from a more personal, practical angle. If you are considering stopping because progress has stalled and you are unsure whether to continue, our page on what happens when you stop Wegovy is a useful starting point before making that decision.

Pausing rather than stopping (under prescriber guidance) may be appropriate in some circumstances, for example around surgery or if side effects are the reason progress has stalled. If your pen feels like it isn't injecting correctly rather than the medicine not working, that is a different problem: pen delivery issues are usually mechanical and solvable without changing your treatment plan at all.

The honest summary: a plateau on Wegovy is worth investigating with your prescriber before drawing conclusions. If you would like a clinical review of where you are with treatment, speak to our prescribers, every consultation is reviewed the same day by a GPhC-registered prescriber, not passed to an algorithm.